跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
XYDALBA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
XYDALBA
Authorized
STANDARD
XYDALBA
Endo Operations Ltd.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
acccc66d122ce88a
Company
Endo Operations Ltd.
Type
Standard
Approval Details
Approval Id
acccc66d122ce88a
Drug Approval Canada Name
XYDALBA
Product Name
XYDALBA
Status
Marketed
Status Date
2021-05-28
Original Market Date
2021-05-28
Din
02480522
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Prescription
Ahfs
08:12.28.16
Atc Original
J01XA04 DALBAVANCIN
Atc Name
j 01 xa 04
Aig Number
0160631001
Company Name
Endo Operations Ltd.
Company Address
1st Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin, Ireland, D04 H9P8
Active Ingredients
DALBAVANCIN (DALBAVANCIN HYDROCHLORIDE)
500 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
acccc66d122ce88a
Type
Standard
Back to Health Canada Approvals